SELLAS Life Sciences Group, Inc.

Sellas Life Sciences Group, Inc.

Biotechnology • Healthcare • New York, NY, United States • SLS (NCM)

SELLAS Life Sciences Group, Inc., a late-stage clinical biopharmaceutical company, focuses on the development of novel therapeutics for various cancer indications in the United States. The company's lead product candidate is galinpepimut-S (GPS), a peptide immunotherapy directed against the Wilms tumor 1, antigen; and SLS009 (tambiciclib), a selective small molecule cyclin-dependent kinase 9, or CDK9, inhibitor. It has a strategic collaboration with Merck & Co., Inc. to evaluate GPS as it is administered in combination with PD1 blocker pembrolizumab in a Phase 1/2 clinical trial enrolling patients in up to five cancer indications, including hematologic malignancies and solid tumors; and GenFleet Therapeutics (Shanghai), Inc. for the development and commercialization of GFH009. SELLAS Life Sciences Group, Inc. is headquartered in New York, New York.

646 200 5278 7 Times Square, New York, NY 10036, United States

Stock Performance (90 Days)

Data through Dec 26, 2025
Price updates on page refresh. Intraday quotes available during market hours (9:30 AM - 4:00 PM EST).

Layoff History

No layoff events recorded for this company.

Recent News

SELLAS Life Sciences Group Stock Soars As It Nears Final Analysis In Cancer Study - Stocktwits
Stocktwits • Dec 29
Leukemia study awaits 80th death to trigger final analysis - Stock Titan
Stock Titan • Dec 29
SELLAS Life Sciences (SLS) stock jumps on Phase 3 AML trial timing update — what investors watch next - ts2.tech
ts2.tech • Dec 30
Sellas Life Sciences Stock Surges After Positive Clinical Trials - StocksToTrade
StocksToTrade • Dec 29
Sellas Life Sciences stock soars after trial update shows slower event rate - Investing.com
Investing.com • Dec 29

Other Biotechnology Companies

View All →
CODEXIS, INC. logo Codexis, Inc.
1 layoff tracked
$144.5M market cap
VERTEX PHARMACEUTICALS INC / MA logo Vertex Pharmaceuticals Inc. / MA
$118.68B market cap
REGENERON PHARMACEUTICALS, INC. logo Regeneron Pharmaceuticals, Inc.
$82.72B market cap
ALNYLAM PHARMACEUTICALS, INC. logo Alnylam Pharmaceuticals, Inc.
$52.92B market cap
ARGENX SE logo Argenx SE
$52.62B market cap
INSMED Inc logo Insmed Inc.
$37.61B market cap

Frequently Asked Questions

Has SELLAS Life Sciences Group, Inc. had layoffs?
No layoff events have been recorded for SELLAS Life Sciences Group, Inc. in our database. This could mean the company has not conducted significant layoffs, or any layoffs have not been publicly reported.
How many employees does SELLAS Life Sciences Group, Inc. have?
SELLAS Life Sciences Group, Inc. has approximately 15 employees.
What industry is SELLAS Life Sciences Group, Inc. in?
SELLAS Life Sciences Group, Inc. operates in the Biotechnology industry, within the Healthcare sector.
Is SELLAS Life Sciences Group, Inc. a publicly traded company?
Yes, SELLAS Life Sciences Group, Inc. is publicly traded under the ticker symbol SLS on the NCM. The company has a market capitalization of approximately $0.42 billion.
Where is SELLAS Life Sciences Group, Inc. headquartered?
SELLAS Life Sciences Group, Inc. is headquartered in New York, NY, United States at 7 Times Square, New York, NY 10036, United States.

Disclaimer

Data aggregated from public sources including WARN notices, SEC filings, press releases, and market data. While we strive for accuracy, information is provided "as-is" for informational purposes only. Always verify critical information with official company sources.

This information does not constitute investment, financial, legal, or career advice. See our Terms of Service, Privacy Policy, and About page for more information.

Found an error? Report it here.